Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.3%

Neg 0% Neu 90.3% Pos 0%

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.

Comments

No comments yet. Be the first!